Literature DB >> 9517289

[Mixed uterine mesodermal sarcoma in the population of southern Israel in the years 1996-1971--clinical and pathological characteristics].

S Ariad1, A Rabinovitz, I Yanai-Inbar, B Piura.   

Abstract

During 1971-1996, 17 patients with mixed mesodermal uterine tumors were treated. Average age at diagnosis was 67.3 years, 12/17 were of European and 5/17 of Afro-Asian extraction. The overall 5-year survival was 21%. 10/17 patients had mixed mesodermal tumors with a heterologous mesenchymal element, and 7/17 had a homologous mesenchymal element (carcinosarcoma). 6/17 had another primary malignancy, including breast cancer (3/17), bilateral metachronous breast tumor (2/17), and malignant lymphoma of the neck region (2/17). All 3 with breast cancer had previously been treated with tamoxifen. I had simultaneous mesodermal tumor and ovarian thecoma. Simultaneous autoimmune manifestations occurred in 2/17, including thrombocytopenic purpura in 1, and myasthenia gravis in another. Mesodermal tumor of the uterus is a relatively rare malignancy with aggressive behavior and poor prognosis. It also had unusual associations with other primary tumors, hormonal treatment, and autoimmune manifestations.

Entities:  

Mesh:

Year:  1998        PMID: 9517289

Source DB:  PubMed          Journal:  Harefuah        ISSN: 0017-7768


  3 in total

Review 1.  Tamoxifen in breast cancer ipse dixit in uterine malignant mixed Müllerian tumor and sarcoma-A report of 8 cases and review of the literature.

Authors:  Ana Luisa Cardoso Vasconcelos; Beatriz Nunes; Catarina Duarte; Vera Mendonça; Joana Ribeiro; Marília Jorge; Isabel Monteiro Grillo
Journal:  Rep Pract Oncol Radiother       Date:  2013-08-12

2.  Primary malignant mixed müllerian mesodermal tumor mimicking a rectosigmoid carcinoma: a case report and review of the literature.

Authors:  Sakshi Kapur; Levin Miles
Journal:  Case Rep Oncol Med       Date:  2014-02-10

3.  Simultaneous bilateral occurrence of a mixed mesodermal tumor and cystadenocarcinoma in the ovary.

Authors:  Gábor Vermes; Nándor Acs; István Szabó; Zoltán Langmár; Balázs Járay; Ferenc Bánhidy
Journal:  Pathol Oncol Res       Date:  2004-06-09       Impact factor: 2.874

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.